Gradient-Boosting Classifiers Combining Vessel Density and Tissue Thickness Measurements for Classifying Early to Moderate Glaucoma.
Aged
Cross-Sectional Studies
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Fundus Oculi
Glaucoma
/ diagnosis
Humans
Intraocular Pressure
Macula Lutea
/ pathology
Male
Middle Aged
Optic Disk
/ pathology
ROC Curve
Retinal Vessels
/ pathology
Severity of Illness Index
Tomography, Optical Coherence
/ methods
Visual Fields
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
14
11
2019
revised:
16
03
2020
accepted:
17
03
2020
pubmed:
31
3
2020
medline:
7
10
2020
entrez:
31
3
2020
Statut:
ppublish
Résumé
To compare gradient-boosting classifier (GBC) analysis of optical coherence tomography angiography (OCTA)-measured vessel density (VD) and OCT-measured tissue thickness to standard OCTA VD and OCT thickness parameters for classifying healthy eyes and eyes with early to moderate glaucoma. Comparison of diagnostic tools. A total of 180 healthy eyes and 193 glaucomatous eyes with OCTA and OCT imaging of the macula and optic nerve head (ONH) were studied. Four GBCs were evaluated that combined 1) all macula VD and thickness measurements (Macula GBC), 2) all ONH VD and thickness measurements (ONH GBC), 3) all VD measurements from the macula and ONH (vessel density GBC), and 4) all thickness measurements from the macula and ONH (thickness GBC). ROC curve (AUROC) analyses compared the diagnostic accuracy of GBCs to that of standard instrument-provided parameters. A fifth GBC that combined all parameters (full GBC) also was investigated. GBCs had better diagnostic accuracy than standard OCTA and OCT parameters with AUROCs ranging from 0.90 to 0.93 and 0.64 to 0.91, respectively. The full GBC (AUROC = 0.93) performed significantly better than the ONH GBC (AUROC = 0.91; P = .036) and the vessel density GBC (AUROC = 0.90; P = .010). All other GBCs performed similarly. The mean relative influence of each parameter included in the full GBC identified a combination of macular thickness and ONH VD measurements as the greatest contributors. GBCs that combine OCTA and OCT macula and ONH measurements can improve diagnostic accuracy for glaucoma detection compared to most but not all instrument provided parameters.
Identifiants
pubmed: 32222368
pii: S0002-9394(20)30124-0
doi: 10.1016/j.ajo.2020.03.024
pmc: PMC7492367
mid: NIHMS1605107
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131-139Subventions
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY027945
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027510
Pays : United States
Organisme : NEI NIH HHS
ID : K12 EY024225
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
JAMA Ophthalmol. 2015 Sep;133(9):1045-52
pubmed: 26203793
Ophthalmology. 2016 Dec;123(12):2509-2518
pubmed: 27769587
Biomed Opt Express. 2012 Dec 1;3(12):3127-37
pubmed: 23243564
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1730-42
pubmed: 10845593
Eye (Lond). 1994;8 ( Pt 3):321-3
pubmed: 7958038
Jpn J Ophthalmol. 2019 May;63(3):276-283
pubmed: 30798379
Sci Rep. 2018 Nov 12;8(1):16685
pubmed: 30420630
Mil Med. 1994 Aug;159(8):553-7
pubmed: 7824147
Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2314-20
pubmed: 22427583
J Glaucoma. 1999 Feb;8(1):77-80
pubmed: 10084278
J Glaucoma. 2010 Mar;19(3):167-75
pubmed: 19528827
Graefes Arch Clin Exp Ophthalmol. 2015 Sep;253(9):1557-64
pubmed: 26255817
IEEE Trans Biomed Eng. 2002 Sep;49(9):963-74
pubmed: 12214886
Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3444-54
pubmed: 12407155
Ophthalmology. 2018 Nov;125(11):1720-1728
pubmed: 29907322
Invest Ophthalmol Vis Sci. 1994 Aug;35(9):3362-73
pubmed: 8056511
Am J Ophthalmol. 2016 Nov;171:75-83
pubmed: 27590118
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2748-2756
pubmed: 29860461
J Glaucoma. 2003 Aug;12(4):340-6
pubmed: 12897579
PLoS One. 2018 Dec 5;13(12):e0207784
pubmed: 30517157
Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:1328-1331
pubmed: 28268570
Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):612-24
pubmed: 24408977
Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2395-402
pubmed: 25897021
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):162-9
pubmed: 11773027
Ophthalmol Glaucoma. 2018 Jul - Aug;1(1):15-22
pubmed: 32672627
Am J Ophthalmol. 2016 Aug;168:237-249
pubmed: 27296492
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT451-9
pubmed: 27409505
Ophthalmology. 2019 Jul;126(7):980-988
pubmed: 30858023
Biometrika. 2009 Jun;96(2):371-382
pubmed: 22822245
Graefes Arch Clin Exp Ophthalmol. 2009 Nov;247(11):1517-30
pubmed: 19579030
Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4147-52
pubmed: 16249492
PLoS One. 2017 May 23;12(5):e0177726
pubmed: 28542342
Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1322-9
pubmed: 15790898
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
Artif Intell Med. 2003 Jan;27(1):65-79
pubmed: 12473392
J Glaucoma. 2017 Jun;26(6):548-554
pubmed: 28333896
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Am J Ophthalmol. 1996 May;121(5):511-21
pubmed: 8610794
BMC Ophthalmol. 2011 Feb 11;11:6
pubmed: 21314957
J Glaucoma. 2007 Jan;16(1):20-8
pubmed: 17224745
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3144-51
pubmed: 15326133
PLoS One. 2014 Aug 28;9(8):e106117
pubmed: 25167053
Ophthalmology. 2019 Apr;126(4):513-521
pubmed: 30578810
J Glaucoma. 2016 Mar;25(3):e196-203
pubmed: 26066503
Invest Ophthalmol Vis Sci. 2008 Mar;49(3):945-53
pubmed: 18326717
Ophthalmology. 2016 Dec;123(12):2498-2508
pubmed: 27726964